Truist Securities has reiterated its Hold rating for Dollar General, lowering the price target from $140 to $135. Analyst Scot Ciccarelli notes better-than-expected comparable sales but expects a backend-loaded year, adjusting 2024/2025 estimates to $7.30/$8.05 from $7.35/$8.20. Despite 4% traffic growth, shopping behaviors reflect a stressed customer base.
Calidi Biotherapeutics shares are trading lower by 30.7% during Friday's session. The company announced a definitive agreement for the immediate exercise of certain warrants.